Abstract
Parkinson’s disease (PD) is a common neurodegenerative disorder, and its association with viral hepatitis has been debated. We performed a meta-analysis to examine the association between PD risk and viral hepatitis. Medline, EMBASE, and the Cochrane library were searched from inception till July 2022. Meta-analysis was conducted using a fixed-effect model with the inverse variance method. Three groups were compared to controls: infection with either hepatitis B or C virus (HBV and HCV, respectively), or coinfection with both viruses. We found 551 records, and six studies comprising of 2,566,947 patients were included in the analysis. PD risk was increased in HCV-infected population (OR 1.10, 95% CI 1.03–1.17, p = 0.005) and (HR 1.37, 95% CI 1.26–1.49, p < 0.001). This increase was not observed for the HBV-infected and HBV–HCV-coinfected coinfection populations. For pooled OR, the risk was significantly lower in HBV-infected (OR 0.79, 95% CI 0.76–0.83, p < 0.001) but not significantly different in HBV–HCV-coinfected populations (OR 0.96, 95% CI 0.82–1.12, p = 0.57). For pooled HR, the risk was significantly higher in both HBV-infected (HR 1.22, 95% CI 1.14–1.31, p < 0.001) and HBV–HCV-coinfected populations (HR 1.29, 95% CI 1.05–1.58, p = 0.013). We found that the risk of PD was increased in the HCV-infected population, but results were inconsistent in those with HBV and HBV–HCV infections. Our findings provide impetus for further clinical and functional studies to unravel the role of the adaptive immune system in PD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data supporting the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
References
Abushouk AI, El-Husseny MWA, Magdy M et al (2017) Evidence for association between hepatitis C virus and Parkinson’s disease. Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol 38:1913–1920. https://doi.org/10.1007/s10072-017-3077-4
Amor S, Puentes F, Baker D, van der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology 129:154–169. https://doi.org/10.1111/j.1365-2567.2009.03225.x
Baizabal-Carvallo JF, Alonso-Juarez M (2020) The role of viruses in the pathogenesis of Parkinson’s disease. Neural Regen Res 16:1200–1201. https://doi.org/10.4103/1673-5374.300437
Cacoub P, Comarmond C, Domont F et al (2016) Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 3:3–14. https://doi.org/10.1177/2049936115585942
Carlson B (2005) HCV testing cost-effective alternative to treating advanced disease. Biotechnol Healthc 2:12–14
Chao C, Ghorpade A (2009) Production and roles of glial tissue inhibitor of metalloproteinases-1 in human immunodeficiency virus-1-associated dementia neuroinflammation: a review. Am J Infect Dis 5:314–320. https://doi.org/10.3844/ajidsp.2009.314.319
Chen C-J, Yang H-I, Iloeje UH, Group TR-HS (2009) Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49:S72–S84. https://doi.org/10.1002/hep.22884
Choi H-Y, Mai TH, Kim K-A et al (2020) Association between viral hepatitis infection and Parkinson’s disease: a population-based prospective study. J Viral Hepat 27:1171–1178. https://doi.org/10.1111/jvh.13346
De Virgilio A, Greco A, Fabbrini G et al (2016) Parkinson’s disease: autoimmunity and neuroinflammation. Autoimmun Rev 15:1005–1011. https://doi.org/10.1016/j.autrev.2016.07.022
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188. https://doi.org/10.1016/0197-2456(86)90046-2
Fletcher NF, McKeating JA (2012) Hepatitis C virus and the brain. J Viral Hepat 19:301–306. https://doi.org/10.1111/j.1365-2893.2012.01591.x
George A, Stead TS, Ganti L (2020) What’s the risk: differentiating risk ratios, odds ratios, and hazard ratios? Cureus 12:e10047. https://doi.org/10.7759/cureus.10047
Gill SS, Hou Y, Ghane T, Pulido OM (2008) Regional susceptibility to domoic acid in primary astrocyte cells cultured from the brain stem and hippocampus. Mar Drugs 6:25–38
Golabi P, Otgonsuren M, Sayiner M et al (2017) The prevalence of Parkinson disease among patients with hepatitis C infection. Ann Hepatol 16:342–348. https://doi.org/10.5604/16652681.1235476
Goldstein L, Fogel-Grinvald H, Steiner I (2019) Hepatitis B and C virus infection as a risk factor for Parkinson’s disease in Israel—a nationwide cohort study. J Neurol Sci 398:138–141. https://doi.org/10.1016/j.jns.2019.01.012
Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284. https://doi.org/10.1002/ana.10277
Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560. https://doi.org/10.1136/bmj.327.7414.557
Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8:382–397. https://doi.org/10.1016/S1474-4422(09)70062-6
Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https://doi.org/10.1186/1471-2288-5-13
Hu S, Chao CC, Ehrlich LC et al (1999) Inhibition of microglial cell RANTES production by IL-10 and TGF-beta. J Leukoc Biol 65:815–821. https://doi.org/10.1002/jlb.65.6.815
Jang H, Boltz DA, Webster RG, Smeyne RJ (2009) Viral parkinsonism. Biochim Biophys Acta 1792:714–721. https://doi.org/10.1016/j.bbadis.2008.08.001
Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501:45–51. https://doi.org/10.1038/nature12481
Kim J-M, Jang ES, Ok K et al (2016) Association between hepatitis C virus infection and Parkinson’s disease. Mov Disord 31:1584–1585. https://doi.org/10.1002/mds.26755
Kronfol Z, Remick DG (2000) Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 157:683–694. https://doi.org/10.1176/appi.ajp.157.5.683
Lane TE, Liu MT, Chen BP et al (2000) A central role for CD4(+) T cells and RANTES in virus-induced central nervous system inflammation and demyelination. J Virol 74:1415–1424. https://doi.org/10.1128/jvi.74.3.1415-1424.2000
Lanini S, Ustianowski A, Pisapia R et al (2019) Viral hepatitis: etiology, epidemiology, transmission, diagnostics, treatment, and prevention. Infect Dis Clin N Am 33:1045–1062. https://doi.org/10.1016/j.idc.2019.08.004
Laskus T, Radkowski M, Adair DM et al (2005) Emerging evidence of hepatitis C virus neuroinvasion. AIDS Lond Engl 19(Suppl 3):S140-144. https://doi.org/10.1097/01.aids.0000192083.41561.00
Lin W-Y, Lin M-S, Weng Y-H et al (2019) Association of antiviral therapy with risk of Parkinson disease in patients with chronic hepatitis C virus infection. JAMA Neurol 76:1019–1027. https://doi.org/10.1001/jamaneurol.2019.1368
Lynch SM, Wu GY (2016) Hepatitis C virus: a review of treatment guidelines, cost-effectiveness, and access to therapy. J Clin Transl Hepatol 4:310–319. https://doi.org/10.14218/JCTH.2016.00027
Lyons PD, Benveniste EN (1998) Cleavage of membrane-associated ICAM-1 from astrocytes: involvement of a metalloprotease. Glia 22:103–112. https://doi.org/10.1002/(sici)1098-1136(199802)22:2%3c103::aid-glia1%3e3.0.co;2-8
Mahul-Mellier A-L, Burtscher J, Maharjan N et al (2020) The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci 117:4971–4982. https://doi.org/10.1073/pnas.1913904117
Marín-Serrano E, Rodríguez-Ramos C, Díaz F et al (2006) Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin. J Viral Hepat 13:230–234. https://doi.org/10.1111/j.1365-2893.2005.00679.x
Meffre C, Le Strat Y, Delarocque-Astagneau E et al (2010) Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors. J Med Virol 82:546–555. https://doi.org/10.1002/jmv.21734
Miklossy J, Doudet DD, Schwab C et al (2006) Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 197:275–283. https://doi.org/10.1016/j.expneurol.2005.10.034
Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71
Pakpoor J, Noyce A, Goldacre R et al (2017) Viral hepatitis and Parkinson disease: a national record-linkage study. Neurology 88:1630–1633. https://doi.org/10.1212/WNL.0000000000003848
Pawlotsky J-M, Negro F, Aghemo A et al (2018) EASL Recommendations on treatment of hepatitis C 2018. J Hepatol 69:461–511. https://doi.org/10.1016/j.jhep.2018.03.026
Pronier C, Guyader D, Jézequel C et al (2018) Contribution of quantitative viral markers to document hepatitis B virus compartmentalization in cerebrospinal fluid during hepatitis B with neuropathies. J Neurovirol 24:769–772. https://doi.org/10.1007/s13365-018-0662-0
Qian L, Flood PM, Hong J-S (2010) Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy. J Neural Transm Vienna Austria 117:971–979. https://doi.org/10.1007/s00702-010-0428-1
Qin X-Y, Zhang S-P, Cao C et al (2016) Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol 73:1316–1324. https://doi.org/10.1001/jamaneurol.2016.2742
Radkowski M, Wilkinson J, Nowicki M et al (2002) Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 76:600–608. https://doi.org/10.1128/jvi.76.2.600-608.2002
Rosenthal E, Cacoub P (2015) Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus 24:469–482. https://doi.org/10.1177/0961203314556140
RStudio Team 2020 (2020) RStudio: integrated development for R. RStudio, PBC, Boston, MA. http://www.rstudio.com/. Accessed 14 Dec 2022
Saravanan S, Velu V, Kumarasamy N et al (2008) The prevalence of hepatitis B virus and hepatitis C virus infection among patients with chronic liver disease in South India. Int J Infect Dis IJID off Publ Int Soc Infect Dis 12:513–518. https://doi.org/10.1016/j.ijid.2008.02.006
Sawada M, Imamura K, Nagatsu T (2006) Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transm Suppl. https://doi.org/10.1007/978-3-211-45295-0_57
Stetler-Stevenson WG (2008) Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 1:re6. https://doi.org/10.1126/scisignal.127re6
Tan E-K, Chao Y-X, West A et al (2020) Parkinson disease and the immune system—associations, mechanisms and therapeutics. Nat Rev Neurol 16:303–318. https://doi.org/10.1038/s41582-020-0344-4
Tsai H-H, Liou H-H, Muo C-H et al (2016) Hepatitis C virus infection as a risk factor for Parkinson disease: a nationwide cohort study. Neurology 86:840–846. https://doi.org/10.1212/WNL.0000000000002307
Weissenborn K, Ennen JC, Bokemeyer M et al (2006) Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 55:1624–1630. https://doi.org/10.1136/gut.2005.080267
Wells G, Wells GA, Wells G, Shea B, Shea B, O’Connell D, Peterson J, Welch LM, Tugwell P, Ga SW, Zello GA, Petersen JA (2014) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Accessed 14 Dec 2022
Wu WY-Y, Kang K-H, Chen SL-S et al (2015) Hepatitis C virus infection: a risk factor for Parkinson’s disease. J Viral Hepat 22:784–791. https://doi.org/10.1111/jvh.12392
Yu M-L, Chuang W-L (2009) Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 24:336–345. https://doi.org/10.1111/j.1440-1746.2009.05789.x
Zhang Y, Cobleigh MA, Lian J-Q et al (2011) A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology 141:1897–1906. https://doi.org/10.1053/j.gastro.2011.06.051
Acknowledgements
TEK is supported by the National Medical Research Council (PD LCG 000207 & STaR).
Author information
Authors and Affiliations
Contributions
Conceptualization was done by CYLY, ASM, E-KT; CYLY, ASYH, NZ-YC, and RIHC were involved in methodology; CYLY, ASYH, NZ-YC, and RIHC helped in formal analysis and investigation; CYLY, ASYH, NZ-YC, and RIHC contributed to writing—original draft preparation; ASM and E-KT contributed to writing—review and editing; funding acquisition: NA; resources: NA; E-KT helped in supervision.
Corresponding author
Ethics declarations
Conflict of interest
The authors have no relevant financial or non-financial interests to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yaow, C.Y.L., Hong, A.S.Y., Chong, N.ZY. et al. Risk of Parkinson’s disease in hepatitis B and C populations: a systematic review and meta-analysis. J Neural Transm (2023). https://doi.org/10.1007/s00702-023-02705-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00702-023-02705-7